pmjТихоокеанский медицинский журналPacific Medical Journal1609-1175TGMU10.34215/1609-1175-2021-1-10-14pmj-2153Research ArticleОБЗОРЫREVIEWSТуберкулез в структуре коморбидной патологии у больных COVID-19Tuberculosis in the structure of COVID-19 patients comorbiditieshttps://orcid.org/0000-0002-9023-6986СтаршиноваА. А.StarshinovaA. A.

Старшинова Анна Андреевна – доктор медицинских наук, начальник управления научными исследованиями.

197341, Cанкт-Петербург, ул. Аккуратова 2

Anna A. Starshinova, MD, PhD, head of the research department.

2 Akkuratova St., Saint-Petersburg, 197341

starshinova_aa@almazovcentre.ruhttps://orcid.org/0000-0001-8383-8519ДовгалюкИ. Ф.DovgalyukI. F.

Довгалюк Ирина Федоровна – доктор медицинских наук, профессор, ведущий научный сотрудник.

191036, Cанкт-Петербург, Лиговский пр-т, 2-4

Irina F. Dovgalyuk, MD, PhD, professor, head of the Phthisopediatrics Department.

2-4 Ligovsky Ave., Saint Petersburg, 191036

prdovgaluk@mail.ruНациональный медицинский исследовательский центр им. В.А. АлмазоваРоссияAlmazov National Medical Research CentreRussian FederationСанкт-Петербургский НИИ фтизиопульмонологииРоссияSaint-Petersburg Research Institute of PhthisiopulmonologyRussian Federation202121032021011014Copyright © Старшинова А.А., Довгалюк И.Ф., 20212021Старшинова А.А., Довгалюк И.Ф.Starshinova A.A., Dovgalyuk I.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tmj-vgmu.ru/jour/article/view/2153

В 2020 г. мир столкнулся с новым инфекционным заболеванием, которое потребовало беспрецедентных эпидемических мероприятий. Пандемия COVID-19 может отразиться на распространенности и течении других болезней, в том числе туберкулезной инфекции. Проведен анализ публикаций в онлайн-базах данных Medline, PubMed и Scopus с описанием сопутствующей патологии у больных новой коронавирусной инфекцией с декабря 2019 по октябрь 2020 г. Были отобраны 32 статьи, в которых представлены сведения о 152 тысячах больных COVID-19, имевших сопутствующую патологию. Наиболее часто среди последней встречались артериальная гипертензия (21,2 %), сахарный диабет (12,1 %), хронические заболевания легких (4,2 %) и онкологические заболевания (0,3 %). Сочетание COVID-19 и туберкулеза регистрировалось разными авторами в 0,3-8,3 % случаев, чаще в странах с высоким бременем туберкулеза (Китай и Индия).

In 2020 the world faced new infectious disease which required unprecedented epidemic measures. The pandemic of COVID-19 can affect the spread and courses of other diseases including tuberculosis infection. The analysis of the publications in online databases Medline, PubMed and Scopus was conducted following the description of the accompanying pathologies of the patients suffering from new coronavirus infection from December 2019 to October 2020. 32 articles presenting information about 152,000 COVID-19 patients having accompanying pathology were chosen. More often such pathologies as arterial hypertension (21.2 %), diabetes (12.1 %), chronic lung diseases (4.2 %) and oncology diseases (0.3 %) were found. The combination of COVID-19 and tuberculosis was registered by different authors in 0.3-8.3 % cases, more often in countries with high level of tuberculosis (China and India).

COVID-19SARS-CoV-2сопутствующая патологиятуберкулезCOVID-19SARS-CoV-2accompanying pathologytuberculosisReferencesSingh A, Prasad R, Gupta A, Das K, Gupta N. Severe acute respiratory syndrome coronavirus-2 and pulmonary tuberculosis: convergence can be fatal (Review). Monaldi Arch Chest Dis. 2020;90(3). doi: 10.4081/monaldi.2020.1368Singh A, Prasad R, Gupta A, Das K, Gupta N. Severe acute respiratory syndrome coronavirus-2 and pulmonary tuberculosis: convergence can be fatal (Review). Monaldi Arch Chest Dis. 2020;90(3). doi: 10.4081/monaldi.2020.1368Togun Т, Kampmann В, Stoker N.G., Lipman M. Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes. Ann Clin Microbiol Antimicrob. 2020;19:21. doi: 10.1186/s12941-020-00363-1Togun Т, Kampmann В, Stoker N.G., Lipman M. Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes. Ann Clin Microbiol Antimicrob. 2020;19:21. doi: 10.1186/s12941-020-00363-1Stochino C, Villa S, Zucchi P, Parravicini P, Gori A, Ravi-glione MC. Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. Eur Respir J. 2020;56:2001708. doi: 10.1183/13993003.01708-2020Stochino C, Villa S, Zucchi P, Parravicini P, Gori A, Ravi-glione MC. Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. Eur Respir J. 2020;56:2001708. doi: 10.1183/13993003.01708-2020Glaziou P Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in 2020. MedRxiv. 2020. doi: 10.1101/2020.04.28.20079582Glaziou P Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in 2020. MedRxiv. 2020. doi: 10.1101/2020.04.28.20079582Chen H, Zhang K. Insight into impact of COVID-19 epidemic on tuberculosis burden in China. Eur Respir J. 2020. doi: 10.1183/13993003.02710-2020Chen H, Zhang K. Insight into impact of COVID-19 epidemic on tuberculosis burden in China. Eur Respir J. 2020. doi: 10.1183/13993003.02710-2020Komiya K, Yamasue M, Takahashi O, Hiramatsu K, Kadota J, Kato S. The COVID-19 pandemic and the true incidence of tuberculosis in Japan. J Infect. 2020;81(3):E24-5. doi: 10.1016/j.jinf.2020.07.004Komiya K, Yamasue M, Takahashi O, Hiramatsu K, Kadota J, Kato S. The COVID-19 pandemic and the true incidence of tuberculosis in Japan. J Infect. 2020;81(3):E24-5. doi: 10.1016/j.jinf.2020.07.004Фтизиатрия. Национальные клинические рекомендации / под ред. П.К. Яблонского. М.: ГЭОТАР-Медиа, 2015.Yablon-sky PK, ed. Phthisiology: National Clinical Guidelines. Moscow: GEOTAR-Media; 2015 (In Russ).Старшинова А.А., Кушнарева Е.А., Малкова А.М., Довга-люк И.Ф., Кудлай Д.А. Новая коронавирусная инфекция: особенности клинического течения, возможности диагностики, лечения и профилактики инфекции у взрослых и детей. Вопросы современной педиатрии. 2020;19(2):123-31.Starshinova AA, Kushnareva EA, Malkova AM, Dovgalyuk IF, Kudlay DA. New coronaviral infection: Features of clinical course, capabilities of diagnostics, treatment and prevention in adults and children. Current Pediatrics. 2020;19(2):123-31 (In Russ).Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features ofpatients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features ofpatients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.Yan CH, Faraji F, Divya P Prajapati DP, Boone CE, DeConde AS. Association of chemosensory dysfunction and COVID-19 in patients presenting with influenzalike symptoms. Int Forum Allergy Rhinol. 2020;10(7):806-13.Yan CH, Faraji F, Divya P Prajapati DP, Boone CE, DeConde AS. Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol. 2020;10(7):806-13.Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy and mortality in COVID-19. New Engl J Med. 2020;382:e102. doi: 10.1056/NEJMoa2007621Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy and mortality in COVID-19. New Engl J Med. 2020;382:e102. doi: 10.1056/NEJMoa2007621Feng Z, Li Q, Zhang Y, Wu Z, Dong X, Ma H, et al. The epidemiological characteristics of an outbreak of 2019 novel Coronavirus Diseases (COVID-19) - China, 2020. China CDC Weekly. 2020;2(8):113-22. doi: 10.46234/ccdcw2020.032Feng Z, Li Q, Zhang Y, Wu Z, Dong X, Ma H, et al. The epidemiological characteristics of an outbreak of 2019 novel Corona-virus Diseases (COVID-19) - China, 2020. China CDC Weekly. 2020;2(8):113-22. doi: 10.46234/ccdcw2020.032Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: A biomarker for CO-VID-19. Int Forum Allergy Rhinol. 2020:10:944-50.Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: A biomarker for CO-VID-19. Int Forum Allergy Rhinol. 2020:10:944-50.Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020;133(9):1025-31.Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020;133(9):1025-31.Chen Y, Wang Y, Fleming J, Yu Y, Gu Y, Liu Ch, et al. Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. MedRxiv. 2020.03.10.20033795; doi: 10.1101/2020.03.10.20033795Chen Y, Wang Y, Fleming J, Yu Y, Gu Y, Liu Ch, et al. Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. MedRxiv. 2020.03.10.20033795; doi: 10.1101/2020.03.10.20033795Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopi-navir-Ritonavir in adults hospitalized with severe Covid-19. New Engl J Med. 2020;382:1787-99. doi: 10.1056/NEJMoa2001282Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopi-navir-Ritonavir in adults hospitalized with severe Covid-19. New Engl J Med. 2020;382:1787-99. doi: 10.1056/NEJMoa2001282Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, at al. Compassionate use of remdesivir for patients with severe Covid-19. New Engl J Med. 2020;382:2327-36. doi: 10.1056/NEJMoa2007016Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, at al. Compassionate use of remdesivir for patients with severe Covid-19. New Engl J Med. 2020;382:2327-36. doi: 10.1056/NEJMoa2007016Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):P1569-78.Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):P1569-78.Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. New Engl J Med. 2020;382:2411-8 doi: 10.1056/NEJMoa2012410Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. New Engl J Med. 2020;382:2411-8 doi: 10.1056/NEJMoa2012410Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020; 117(20):10970-5.Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020; 117(20):10970-5.Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: A retrospective cohort study. Lancet Rheumatol. 2020;2(6):E325-31. doi: 10.1016/S2665-9913(20)30127-2Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: A retrospective cohort study. Lancet Rheumatol. 2020;2(6):E325-31. doi: 10.1016/S2665-9913(20)30127-2Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;81(2)P318-56.Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Go-letti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;81(2)P318-56.Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. New Engl J Med. 2020;383:517-25. doi: 10.1056/NEJMoa2016638Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lof-gren SM, Okafor EC, et al. A Randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. New Engl J Med. 2020;383:517-25. doi: 10.1056/NEJMoa2016638Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Monte-jano R, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. New Engl J Med. 2020;383:1827-37. doi: 10.1056/NEJMoa2015301Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Monte-jano R, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. New Engl J Med. 2020;383:1827-37. doi: 10.1056/NEJMoa2015301Freedberg DE, Conigliaro J, Sobieszczyk ME, Markowitz DD, Gupta A, O’Donnell MR, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. Gastroenterol. 2020;159:1129-31. doi: 10.1053/j.gastro.2020.05.053Freedberg DE, Conigliaro J, Sobieszczyk ME, Markowitz DD, Gupta A, O’Donnell MR, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. Gastroenterol. 2020;159:1129-31. doi: 10.1053/j.gastro.2020.05.053Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19 -Preliminary Report. New Engl J Med. 2020. doi: 10.1056/NEJ-Moa2021436Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19 -Preliminary Report. New Engl J Med. 2020. doi: 10.1056/NEJ-Moa2021436Mather JF, Seip RL, McKay RG. Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19. Am J Gastroenterol. 2020;115(10):1617-23.Mather JF, Seip RL, McKay RG. Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19. Am J Gastroenterol. 2020;115(10):1617-23.Shao Z, Feng Y, Zhong L, Xie Q, Lei M, Liu Z, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: A multicenter retrospective cohort study. Clin Transl Immunol. 2020;e1192. doi: 10.1002/cti2.1192Shao Z, Feng Y, Zhong L, Xie Q, Lei M, Liu Z, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: A multicenter retrospective cohort study. Clin Transl Immunol. 2020;e1192. doi: 10.1002/cti2.1192Khamis F, Al-Zakwani I, Al Hashmi S, Al Dowaiki S, Al Bah-rani M, Pandak N, et al. Therapeutic plasma exchange in adults with severe COVID-19 infection. Int J Infect Dis. 2020;99:214-8.Khamis F, Al-Zakwani I, Al Hashmi S, Al Dowaiki S, Al Bah-rani M, Pandak N, et al. Therapeutic plasma exchange in adults with severe COVID-19 infection. Int J Infect Dis. 2020;99:214-8.Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. JAMA. 2020;324(5):460-70.Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. JAMA. 2020;324(5):460-70.Gharbharan A, Jordans CCE, Geurtsvankessel C, den Hollander GJ, Karim F, Mollema FPN, et al. Convalescent plasma for COVID-19: A randomized clinical trial. MedRxiv. 2020. doi: 10.1101/2020.07.01.20139857.Gharbharan A, Jordans CCE, Geurtsvankessel C, den Hollander GJ, Karim F, Mollema FPN, et al. Convalescent plasma for COVID-19: A randomized clinical trial. MedRxiv. 2020. doi: 10.1101/2020.07.01.20139857.Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, et al. Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). MedRxiv. 2020. doi: 10.1101/2020.09.03.20187252Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, et al. Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). MedRxiv. 2020. doi: 10.1101/2020.09.03.20187252Liu STH, Lin H-M, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent plasma treatment of severe COVID-19: A propensity score-matched control study. Nat Med. 2020;26:1708-13.Liu STH, Lin H-M, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent plasma treatment of severe COVID-19: A propensity score-matched control study. Nat Med. 2020;26:1708-13.Stone JH, Frigault MJ , Serling-Boyd NJ, Fernandes AD , Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. New Engl J Med. 2020;383:2333-4. doi: 10.1056/NEJMoa2028836Stone JH, Frigault MJ , Serling-Boyd NJ, Fernandes AD , Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. New Engl J Med. 2020;383:2333-4. doi: 10.1056/NEJMoa2028836Tsai A, Diawara O, Nahass RG, Brunetti L. Impact oftocilizumab administration on mortality in severe COVID-19. MedRxiv. 2020. doi: 10.1101/2020.07.30.20114959Tsai A, Diawara O, Nahass RG, Brunetti L. Impact oftocilizumab administration on mortality in severe COVID-19. MedRxiv. 2020. doi: 10.1101/2020.07.30.20114959Rojas-Marte G, Khalid M, Mukhtar O, Hashmi AT, Waheed MA, Ehrlich S, et al. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: A case-controlled study. QJM: An International Journal of Medicine. 2020;113(8):546-50.Rojas-Marte G, Khalid M, Mukhtar O, Hashmi AT, Waheed MA, Ehrlich S, et al. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: A casecontrolled study. QJM: An International Journal of Medicine. 2020;113(8):546-50.Colaneri M, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V, Bran-dolino F, et al. Tocilizumab for treatment of severe COVID-19 patients: Preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms. 2020;8(5):695. doi: 10.3390/mi-croorganisms8050695Colaneri M, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V, Brandolino F, et al. Tocilizumab for treatment of severe COVID-19 patients: Preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms. 2020;8(5):695. doi: 10.3390/mi-croorganisms8050695Salvarani C, Dolci G, Massari M; Merlo DF, Cavuto S, Savoldi L, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial. JAMA Intern Med. 2021;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615 (Published online Oct. 20, 2020).Salvarani C, Dolci G, Massari M; Merlo DF, Cavuto S, Savoldi L, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial. JAMA Intern Med. 2021;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615 (Published online Oct. 20, 2020).Horby P, Mafham M, Linsell L, Phil D, Bell JL, Staplin N, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. New Engl J Med. 2020;383:2030-40. doi: 10.1056/NEJMoa2022926Horby P, Mafham M, Linsell L, Phil D, Bell JL, Staplin N, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. New Engl J Med. 2020;383:2030-40. doi: 10.1056/NEJMoa2022926Мелехина Е.В., Горелов А.В., Музыка А.Д. Клинические особенности течения COVID-19 у детей различных возрастных групп. Обзор литературы к началу апреля 2020 года. Вопросы практической педиатрии. 2020;15(2):7-20. doi: 10.20953/1817-7646-20202-7-20Melekhina EV, Gorelov AV, Muzyka AD. Clinical features of the cours of CO-VID-19 in children of various age groups: Literature review by early April 2020. Clinical Practice in Pediatrics. 2020;15(2):7-20 (In Russ). doi: 10.20953/1817-7646-20202-7-20Goussard P, Solomons RS, Andronikou S, Mfingwana L, Verha-gen LM, Rabie Н. COVID-19 in a child with tuberculous airway compression. Pediatr Pulmonol. 2020;55:2201-3.Goussard P, Solomons RS, Andronikou S, Mfingwana L, Verha-gen LM, Rabie Н. COVID-19 in a child with tuberculous airway compression. Pediatr Pulmonol. 2020;55:2201-3.Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: A modelling study. Lancet Glob Health. 2020;8(9):e1132-41. doi: 10.1016/S2214-109X(20)30288-6Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: A modelling study. Lancet Glob Health. 2020;8(9):e1132-41. doi: 10.1016/S2214-109X(20)30288-6Забозлаев Ф.Г., Кравченко Э.В., Галлямова А.Р, Летунов-ский Н.Н. Патологическая анатомия легких при новой коронавирусной инфекции (COVID-19). Предварительный анализ аутопсийных исследований. Клиническая практика. 2020;11(2):21-37.Zabozlaev FG, Kravchenko EV, Gallyamova AR, Letunovskiy NN. Pulmonary pathology of the new coronavirus disease (Covid-19): The preliminary analysis ofpost-mortem findings. Journal of Clinical Practice. 2020;11(2):21-37 (In Russ).

The authors declare that there are no conflicts of interest present.